Advance of Mechanisms and Clinical Applications about Rapamycin for Treating Immune Mediated Hemocytopenia--Review.
10.7534/j.issn.1009-2137.2018.06.043
- Author:
Hao GU
1
;
Run-Hui WU
2
Author Information
1. Department of Hematology and Oncology，Beijing Children's Hospital，Capital Medical University，Beijing 100045，China.
2. Department of Hematology and Oncology，Beijing Children's Hospital，Capital Medical University，Beijing 100045，China E-mail：runhuiwu@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Anemia, Aplastic;
Humans;
Quality of Life;
Sirolimus;
therapeutic use;
T-Lymphocytes, Regulatory;
TOR Serine-Threonine Kinases
- From:
Journal of Experimental Hematology
2018;26(6):1836-1840
- CountryChina
- Language:Chinese
-
Abstract:
Immune-mediated hemocytopenia is a common cytopenic diseases without bone marrow hematopoietic abnormalities, the patient's quality of life is significantly reduced when first-line treatments are ineffective. Rapamycin, possesses a clear mechanism of targeting mTOR protein, can upregulate regulatory T cells and induces apoptosis of specific cells, by regulating the lymphocyte subsets, so as to treat various types of immune-mediated hemocytopenia with a certain therapeutic effect. In this reviews, the action mechanism and clinical application of rapamycin in immune thrombocytopenia（ITP）, autoimmune hemolytic anemia（AIHA）, acquired aplastic anemia and autoimmune lymphoproliferative syndrome（ALPS） etc. are summarized.
